Cargando…

Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry

INTRODUCTION: Phase III clinical trials of dexamethasone intravitreal implant for diabetic macular oedema (DMO) have reported significant improvements in visual acuity (VA). Studies evaluating the treatment of DMO in routine clinical practice provide data to identify areas that need improvement. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandari, Sanjeeb, Gabrielle, Pierre-Henry, Nguyen, Vuong, Daien, Vincent, Viola, Francesco, Bougamha, Walid, Young, Stephanie, Romero-Nuñez, Barbara, Figueras-Roca, Marc, Zarranz-Ventura, Javier, Barthelmes, Daniel, Sararols, Laura, Gillies, Mark, Creuzot-Garcher, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927495/ https://www.ncbi.nlm.nih.gov/pubmed/35179714 http://dx.doi.org/10.1007/s40123-022-00473-3

Ejemplares similares

Initial observation or treatment for diabetic macular oedema with good visual acuity: two‐year outcomes comparison in routine clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2020)

Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2‐year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2021)

THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
por: Bhandari, Sanjeeb, et al.
Publicado: (2022)

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry
por: Niedzwiecki, Mateusz, et al.
Publicado: (2021)

Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience
por: Debourdeau, Eloi, et al.
Publicado: (2023)

Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2021)

Neovascular age‐related macular degeneration: A review of findings from the real‐world Fight Retinal Blindness! registry
por: Nguyen, Vuong, et al.
Publicado: (2021)

Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age‐related macular degeneration in daily clinical practice: data from the FRB! registry
por: Gabrielle, Pierre‐Henry, et al.
Publicado: (2022)

A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
por: Ang, Juan Lyn, et al.
Publicado: (2020)

Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes
por: Zarranz-Ventura, Javier, et al.
Publicado: (2020)

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema
por: Cornish, Elisa E, et al.
Publicado: (2023)

Save our Sight (SOS): a collective call-to-action for enhanced retinal care across health systems in high income countries
por: Loewenstein, Anat, et al.
Publicado: (2023)

Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world
por: Zarranz-Ventura, Javier, et al.
Publicado: (2019)

Comparison of two techniques used in routine care for the treatment of inflammatory macular oedema, subconjunctival triamcinolone injection and intravitreal dexamethasone implant: medical and economic importance of this randomized controlled trial
por: Couret, Chloé, et al.
Publicado: (2020)

Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema
por: Karttunen, Tommi, et al.
Publicado: (2019)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Effectiveness of 190 µg Fluocinolone Acetonide and 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis
por: Zarranz-Ventura, Javier, et al.
Publicado: (2020)

Topical Antibiotic Prophylaxis and Intravitreal Injections: Impact on the Incidence of Acute Endophthalmitis—A Nationwide Study in France from 2009 to 2018
por: Baudin, Florian, et al.
Publicado: (2022)

Repeatability and reproducibility of retinal and choroidal thickness measurements in Diabetic Macular Edema using Swept-source Optical Coherence Tomography
por: Sala-Puigdollers, Anna, et al.
Publicado: (2018)

Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
por: Majumder, Parthopratim Dutta, et al.
Publicado: (2016)

Change in choroidal volume after dexamethasone intravitreal implant in eyes with diabetic macular oedema
por: Posch‐Pertl, Laura, et al.
Publicado: (2018)

Comment on “Effectiveness of 190 µg Fluocinolone Acetonide versus 700 µg Dexamethasone Intravitreal Implants in Diabetic Macular Edema Using the Area-Under-the-Curve Method: The CONSTANT Analysis” [Response to Letter]
por: Zarranz-Ventura, Javier, et al.
Publicado: (2020)

Incidence and Prevalence of Neovascular Age-Related Macular Degeneration in France between 2008 and 2018: The LANDSCAPE Study
por: Creuzot-Garcher, Catherine P., et al.
Publicado: (2022)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
por: Loutfi, Mohamed, et al.
Publicado: (2014)

Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
por: Shibeeb, O'Sam, et al.
Publicado: (2014)

Cost‐effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov‐model
por: Pesonen, Mari, et al.
Publicado: (2021)

Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial
por: O’Day, Roderick F, et al.
Publicado: (2014)

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
por: Hunt, Adrian Robert, et al.
Publicado: (2023)

Prospective, Observational, Multicenter, Real-World Study of the Efficacy, Safety, and Pattern of Use of the Dexamethasone Intravitreal Implant in Diabetic Macular Edema in France: Short-Term Outcomes of LOUVRE 3
por: Kodjikian, Laurent, et al.
Publicado: (2023)

Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema
por: Abdel-Hay, Ahmed, et al.
Publicado: (2018)

Œdema and Scabies in a Famine Hospital
por: Bhandari, B. N.
Publicado: (1944)

Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study
por: Fraser-Bell, Samantha, et al.
Publicado: (2023)

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study
por: Mitchell, Paul, et al.
Publicado: (2023)

Bilateral acute macular neuroretinopathy in a young woman after the first dose of Oxford–AstraZeneca COVID-19 vaccine
por: Gabrielle, Pierre-Henry, et al.
Publicado: (2022)

Longer treatment intervals are associated with reduced treatment persistence in neovascular age related macular degeneration
por: Teo, Kelvin Y. C., et al.
Publicado: (2022)

Association between the retinal vascular network with Singapore "I" Vessel Assessment (SIVA) software, cardiovascular history and risk factors in the elderly: The Montrachet study, population-based study
por: Arnould, Louis, et al.
Publicado: (2018)

Gastrointestinal tract obstruction secondary to post-operative oedema: does dexamethasone administration help?
por: Atie, M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5oh3s0h1hgm5icnerf2jr36rct